Doylestown-based Aprea Therapeutics, a leader in precision oncology, has successfully secured a financing deal anticipated to bring in up to $34 million in proceeds, writes John George for the Philadelphia Business Journal.  

The Bucks County-based company announced a securities purchase agreement with a mix of new and existing investors and some undisclosed insiders, initially providing $16 million upfront.  

This agreement opens the door for an additional $18 million through the exercise of warrants at the investors’ discretion. 

This influx of funds, spearheaded by Sphera Healthcare and supported by notable investors like Nantahala Capital and DAFNA Capital Management, will fuel Aprea’s innovative research in synthetic lethality and DNA damage response. 

Among the advancements being supported is the phase 1 clinical trial of APR-1051, aimed at treating Cyclin E over-expressing cancers, and the development of ATRN-119 for solid tumors. 

Despite a more than 12 percent drop in its stock price following the announcement, Aprea remains optimistic.  

The funds are expected to sustain the company’s operations into 2026, highlighting the potential for significant advancements in cancer treatment. 

Aprea, originally founded in Stockholm in 2002 and boasting a compact team of about 10 employees, continues to push the boundaries of oncology research from its new Bucks County base. 

Read more about Aprea Therapeutics’ new financial deal in the Philadelphia Business Journal.  

Doylestown PA | The History of Philadelphia Suburb in Bucks County